STOCK TITAN

Vision Sensing Acquisition Corp. Receives Positive Ruling from Nasdaq Hearings Panel

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) announces a positive ruling from the Nasdaq Hearings Panel regarding non-compliance issues related to the market value requirement and total holders requirement. The company submitted an appeal with a detailed Compliance Plan to regain compliance, citing the upcoming business combination with Mediforum Co., as a solution. The Panel granted the request for the company to continue its listing on Nasdaq, subject to certain conditions.
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) annuncia una decisione positiva del Panel di Udienze Nasdaq riguardo a problemi di non conformità legati al requisito del valore di mercato e al numero totale di detentori. La società ha presentato un ricorso con un dettagliato Piano di Conformità per riacquistare la conformità, citando la prossima combinazione aziendale con Mediforum Co. come soluzione. Il Panel ha concesso alla società di continuare la sua quotazione su Nasdaq, a condizione di certi requisiti.
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) anuncia un fallo positivo del Panel de Audiencias de Nasdaq respecto a problemas de incumplimiento relacionados con el requisito de valor de mercado y el requisito de total de tenedores. La compañía presentó una apelación con un Plan de Cumplimiento detallado para recuperar el cumplimiento, mencionando la próxima combinación de negocios con Mediforum Co. como solución. El Panel concedió la solicitud de la compañía para continuar su cotización en Nasdaq, sujeto a ciertas condiciones.
Vision Sensing Acquisition Corp. (나스닥: VSACU, VSAC, VSACW)는 시장 가치 요건 및 총 보유자 요건과 관련된 불일치 문제에 대해 나스닥 청문회 패널의 긍정적인 판결을 발표합니다. 회사는 Mediforum Co.와의 예정된 사업 결합을 해결책으로 인용하며, 준수 계획을 자세히 제출하여 준수 상태를 회복하기 위한 상소를 제출했습니다. 패널은 일정 조건을 전제로 회사가 나스닥에 계속 상장할 수 있도록 요청을 승인했습니다.
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) annonce une décision positive du Panel d’Auditions de Nasdaq concernant des problèmes de non-conformité liés à l’exigence de valeur de marché et au nombre total de détenteurs. L'entreprise a soumis un appel avec un Plan de Conformité détaillé pour retrouver la conformité, citant la future combinaison d'affaires avec Mediforum Co. comme solution. Le Panel a accordé à l'entreprise le droit de continuer sa cotation sur le Nasdaq, sous certaines conditions.
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) verkündet ein positives Urteil des Nasdaq-Anhörungspanels bezüglich der Nichteinhaltung von Anforderungen zum Marktwert und zur Gesamtanzahl der Halter. Das Unternehmen reichte einen detaillierten Compliance-Plan zur Wiedererlangung der Konformität ein, wobei die bevorstehende Geschäftsübernahme mit Mediforum Co. als Lösung angeführt wurde. Das Panel genehmigte den Antrag des Unternehmens, seine Notierung an der Nasdaq unter bestimmten Bedingungen fortzusetzen.
Positive
  • None.
Negative
  • None.

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company” or “VSAC”), a special purpose acquisition company, issues an update regarding the previously announced staff determination letter (the "Letter") received on January 17, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the determination from the Nasdaq Staff (the "Staff").

As stated, the Letter was issued to the Company as the Company is not in compliance with the market value requirement as set forth Listing Rule 5450(b)(2)(A) (the “Market Value Requirement”), and the minimum 400 total holders requirement, as is required by Listing Rule 5450(a)(2) (the “Total Holders Requirement”). The Letter also states that the Company has not yet filed its Form 10-Q for the period ended September 30, 2023 (the “Filing”) and is therefore not in compliance with Listing Rule 5250(c)(1).

On January 23, 2024, the Company submitted an appeal to the appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. This submission included a detailed Compliance Plan, to present to the Panel, to regain compliance with the Listing Rules and also requested a stay of the suspension of the Company’s securities. The Hearing request has stayed the suspension of the Company’s securities and the filing of the Form 25-NSE with the Securities and Exchange Commission (the "SEC"). On January 24, 2024, the Company was notified, by the Nasdaq Hearings Advisor, that the hearing is scheduled to be held on April 4, 2024. The Company's securities are still eligible to trade on Nasdaq.

VSAC noted that the deficiencies related to the Market Value Requirement and the Total Holders Requirement are common for SPACs at the Company's current stage of completing a planned transaction. In its Compliance Plan submitted to Staff, VSAC has noted that the recently announced business combination with Mediforum Co., Ltd. (“Mediforum”) will automatically resolve these deficiencies. The Company also noted that, if necessary, it can also consider implementing alternative solutions to the deficiencies to regain compliance with (a) the Market Value Requirement, by converting its Series B shares into Series A shares coupled with moving the company’s listing to the Nasdaq Capital Market and (b) the Total Holders Requirement, by working with outside agencies to increase the number of Total Holders to above the minimum requirement.

On, February 7, 2024, the Company filed the outstanding 10-Q and regained compliance with Listing Rule 5250(c)(1).

On April 4, 2024, the Company met with the Nasdaq Hearings Panel (“Panel”) and the Company management addressed Staff’s concerns regarding timing issues in the business combination and presented a viable, concrete plan to regain compliance within the Panel’s discretionary period while continuing to pursue a business combination.

On April 17, 2024, the Panel granted the request of VSAC to continue its listing on The Nasdaq Stock Market subject to the condition that on or before July 15, 2024, the Company will transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market and comply with all the applicable listing requirements of the Nasdaq Capital Market.  The Company must provide prompt notification of any significant events that occur during this period that may affect the Company’s compliance with the Nasdaq requirements, and the Nasdaq Hearing Panel reserves the right to reconsider the extension based on any event, condition or circumstance that exists or develops that would, in the opinion of the panel, make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted.  The Company intends to vigorously pursue its plan to return to compliance with the Nasdaq listing criteria on or prior to July 15, 2024.

The press release shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act regardless of any general incorporation language in the filing.

About Vision Sensing Acquisition Corp.

Vision Sensing Acquisition Corp. (“VSAC”) is a Special Purpose Acquisition Company (“SPAC”) that has been established to focus on the acquisition of vision sensing technologies (“VST”) including hardware solutions (chips / modules / systems), related application software, artificial intelligence and other peripheral technologies that assist to integrate and/or supplement VST applications. For more information visit www.vision-sensing.com. 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. the Company’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, risks and uncertainties described in reports and other public filings with the SEC by the Company, including the Company’s Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 24, 2023 and its most recent Forms 10-Q, as filed with the SEC on May 15, 2023 and August 28, 2023. These risk factors are not exclusive. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. There may be additional risks that the Company does presently know, or that the Company currently believes are immaterial, that could cause actual results to differ from those contained in the forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

SOURCE: Vision Sensing Acquisition Corp.

 


FAQ

What was the issue that Vision Sensing Acquisition Corp. (VSAC) faced with Nasdaq?

VSAC faced non-compliance with the market value requirement and total holders requirement set by Nasdaq.

What actions did Vision Sensing Acquisition Corp. take to address the non-compliance issues?

VSAC submitted an appeal to the Nasdaq Hearings Panel and presented a detailed Compliance Plan to regain compliance.

What was the outcome of the meeting with the Nasdaq Hearings Panel?

The Panel granted VSAC the request to continue its listing on Nasdaq, subject to transferring its listing to the Nasdaq Capital Market by July 15, 2024.

How did Vision Sensing Acquisition Corp. plan to resolve the non-compliance issues?

VSAC mentioned that the upcoming business combination with Mediforum Co., would automatically resolve the deficiencies.

What is the deadline for Vision Sensing Acquisition Corp. to transfer its listing to the Nasdaq Capital Market?

The company must transfer its listing by July 15, 2024, and comply with all applicable listing requirements.

Why did Vision Sensing Acquisition Corp. file the outstanding 10-Q on February 7, 2024?

VSAC filed the 10-Q to regain compliance with Listing Rule 5250(c)(1) as per Nasdaq's requirements.

Vision Sensing Acquisition Corp.

NASDAQ:VSAC

VSAC Rankings

VSAC Latest News

VSAC Stock Data

48.40M
1.61M
41.7%
86.46%
0.06%
Shell Companies
Blank Checks
United States of America
MIAMI